BioStem Technologies, Inc.
corporate_fare Company Profile
BioStem Technologies, Inc. (NASDAQ:BSEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for BSEM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BSEM spans 8-K, 424B3, S-1, 10-Q.
Recent high-impact activity:
- BioStem Raises $3M in Private Placement While $10M BioTissue Payment Remains Unpaid
- BioStem Registers 12.05M Shares for $40M Roth Equity Facility — Up to 40% Dilution
- BioStem Registers 12.05M Shares for $40M Roth Equity Facility — Potential 40% Dilution
- BioStem Secures $40M Committed Equity Facility with Roth Principal Investments
- BioStem Q2 Revenue Jumps 29% Sequentially; Raises Full-Year Guidance
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 133,922 shares in BSEM as of the September 15, 2026 settlement, a 12.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 77.1% of BSEM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BSEM, detected from its recent SEC filings · based on capital-structure filings through 2026-09-29.
$40M Equity Facility Activated · Up to 40.2% Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →